Correlation Between PET/CT Imaging and a Blood Biomarker in Patients with Metastatic Melanoma Treated with Immunotherapy

Inclusion Criteria

• * Willing to provide informed consent * Must have a metastatic melanoma diagnosis (stage IV) for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned * Must be planning to participate in Signatera™ (ctDNA) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy * Individuals at least 18 years of age * Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study * Willing to comply with all study procedures and be available for the duration of the study

Exclusion Criteria

• * Not able to receive treatment with ICI therapy * Use of investigational drugs, biologics, or devices within 30 days prior to enrollment * Women who are pregnant, lactating, or planning on becoming pregnant during the study * Not suitable for study participation due to other reasons at the discretion of the investigators